EBITDA grew up by 43% YoY to touch ₹187 crore in Q4 FY25
The company’s operating EBITDA stood at ₹6,378 crore. EBITDA margin in the quarter was 14.2%.
Company's EBITDA Margin increased to 13.20% compared to 11.98% in the same period of the previous year
The company’s revenue from operations was at ₹2,694.4 crore, down 11.7% from ₹3,052 crore in Q4 FY24.
Both treatments have already received approvals in India and are available for sale there with local partners under a brand known as Tyvalzi and Lyfaquin.
Operating margins expanded sharply to 15.2% in the March quarter compared to 12% a year ago
They are the generic form of Absorica, a well-known prescription treatment for severe and hard to treat forms of nodular acne that the patient has not responded well to other treatments with.
In the financial year ended 2025, the business added 257 new stores. In the previous comparable period, the business opened 539 stores.
Commissioned by the Andhra Pradesh government as part of its renewable energy drive, the project was awarded to Bondada Engineering.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132 (Member ID - NSE: 10975 BSE: 179 MCX: 55995 NCDEX: 01249), DP SEBI Reg. No. IN-DP-185-2016, PMS SEBI Regn. No: INP000002213, IA SEBI Regn. No: INA000000623, Merchant Banker SEBI Regn. No. INM000010940, RA SEBI Regn. No: INH000000248, BSE Enlistment Number (RA): 5016, AMFI-Registered Mutual Fund Distributor & SIF Distributor
ARN NO : 47791 (Date of initial registration – 17/02/2007; Current validity of ARN – 08/02/2027), PFRDA Reg. No. PoP 20092018, IRDAI Corporate Agent (Composite) : CA1099
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
